New drug for stiff person syndrome granted fast-track designation from FDA | Fox News
Kyverna Therapeutics' KYV-101, a new CAR-T cell therapy for stiff person syndrome, received FDA's RMAT designation, promising accelerated development and approval. The therapy aims to reset patients' immune systems, offering hope for durable remission. Clinical trials show positive results, with ongoing studies for multiple sclerosis, myasthenia gravis, systemic sclerosis, and lupus.
Reference News
Kyverna Therapeutics' KYV-101, a new CAR-T cell therapy for stiff person syndrome, received FDA's RMAT designation, promising accelerated development and approval. The therapy aims to reset patients' immune systems, offering hope for durable remission. Clinical trials show positive results, with ongoing studies for multiple sclerosis, myasthenia gravis, systemic sclerosis, and lupus.